The goal of this clinical trial is to determine how Qlosi™ (pilocarpine HCL ophthalmic solution) 0.4%impacts the quality of life of participants with presbyopia by using a battery of validated and investigator-developed instruments
* Improvement in presbyopic symptoms as measured with the Near Activity Visual Questionnaire-Presbyopia (NAVQ-P) when using Qlosi™ at week 4 compared to baseline (continuous variable).
* Improvement in presbyopic symptoms as measured with the Visual Quality of Life with Time Survey (VisQualT) questionnaire when using Qlosi™ at week 4 compared to baseline.

Start Date18 Jul 2025

Sponsor / Collaborator

Southern College of Optometry

TCTR20250618006

/ Not yet recruitingPhase 3IIT

Low-Dose Pilocarpine for Prevention of Radiation-Induced Xerostomia in Head and Neck Cancer Patients : A Randomized, Double blind, Placebo-Controlled Trial

Start Date01 Jul 2025

Sponsor / Collaborator-

CTR20252115

/ CompletedPhase 1

盐酸毛果芸香碱滴眼液人体药代动力学试验

[Translation] Pharmacokinetics of pilocarpine hydrochloride eye drops in humans

评价盐酸毛果芸香碱滴眼液在中国健康受试者中多次给药后的药代动力学特征。评价盐酸毛果芸香碱滴眼液在中国健康受试者中多次给药后的安全性。

[Translation]

To evaluate the pharmacokinetic characteristics of pilocarpine hydrochloride eye drops after multiple administration in healthy Chinese subjects. To evaluate the safety of pilocarpine hydrochloride eye drops after multiple administration in healthy Chinese subjects.

Start Date02 Jun 2025

Sponsor / Collaborator

Beijing Winsunny Pharmaceutical Co., Ltd.

100 Clinical Results associated with Pilocarpine Hydrochloride

100 Translational Medicine associated with Pilocarpine Hydrochloride

100 Patents (Medical) associated with Pilocarpine Hydrochloride

8,371

Literatures (Medical) associated with Pilocarpine Hydrochloride

31 Dec 2025·Organogenesis

Baicalein Alleviates Lithium-Pilocarpine-Induced Status Epilepticus by Regulating DNMT1/GABRD Pathway in Rats

Article

Author: Yin, Deju ; Liu, Jing ; Huang, Yujing ; Huang, Jing ; Wang, Pengfei ; Wu, Zhenggang

BACKGROUND:

Epilepsy is a common disease of the nervous system. Recent advances in epigenetics have revealed DNA methylation as a key mechanism in epilepsy pathogenesis, particularly through dysregulation of GABAergic signaling. Baicalein has been shown to have anticonvulsant and neuroprotective effects. However, its epigenetic regulatory effects on GABA receptor function remain unexplored.

METHODS:

The status epilepticus (SE) model was induced by lithium chloride-pilocarpine (LiCl-PILO) in Sprague-Dawley (SD) rats. The rats were divided into control group, epileptic SE group and baicalein intervention group. Morris water maze (MWM) test, Nissl staining, immunofluorescence and enzyme-linked immunosorbent assay (ELISA) were used to detect cognitive functions and neuronal damage. Online sites, chromatin immunoprecipitation (ChIP) and western blotting were used to identify DNA methyltransferase 1 (DNMT1)-mediated methylation of gamma-aminobutyric acid type A receptor subunit delta (GABRD) promoter region.

RESULTS:

Baicalein treatment significantly prolonged the latency of SE onset and seizure onset, and improved the development of epilepsy. Meanwhile, baicalein improved the cognitive impairment in rats induced by LiCl-PILO. After treatment with baicalein, a sustained elevation in the number of neurons and NeuN levels was observed, along with a decrease in the contents of tumor necrosis factor -alpha (TNF-α), interleukin-1β (IL-1β), and ionized calcium-binding adapter molecule 1 (Iba-1) in the hippocampus. Mechanistically, baicalein interacted with DNMT1 to suppress GABRD promoter region methylation, thus increasing GABRD protein level in the hippocampus of rats induced by LiCl-PILO.

CONCLUSION:

This study identifies DNMT1/GABRD axis as a novel epigenetic target for epilepsy intervention. Baicalein's ability to enhance tonic inhibition through demethylation of GABRD provides a groundbreaking strategy for drug-resistant epilepsy.

01 Dec 2025·AMERICAN JOURNAL OF OPHTHALMOLOGY

Short-Term Efficacy and Safety of Pilocarpine Ophthalmic Solution for Presbyopia: A Systematic Review and Meta-Analysis

Review

Author: Sampaio, Carlos Augusto Ferraresi ; Mora-Paez, Denisse J ; Amaral, Dillan Cunha ; Guedes, Jaime ; Sampaio, Leonardo Machado ; Sobrinho, Edmundo Frota de Almeida ; Silva, Lucas Dias ; Ribeiro Dos Santos, Leticia ; Ivanov, Yuri Aleksander ; Lima, Gabriel Nery ; Fontes, Bruno Machado

TOPIC:

This systematic review and meta-analysis (SRMA) addresses the clinical question: In patients with presbyopia, how does pilocarpine compare to a vehicle in improving near-vision acuity over a minimum follow-up of 2 weeks? Randomized clinical trials (RCTs) were included to assess the effectiveness of pilocarpine, an FDA-approved pharmacological alternative to traditional corrective measures.

CLINICAL RELEVANCE:

Presbyopia is a progressive age-related condition affecting near vision, impacting approximately 1.8 billion people worldwide. Glasses and contact lenses have limitations and can cause discomfort. In 2021, the FDA approved 1.25% pilocarpine hydrochloride ophthalmic solution (Vuity^Ⓡ) as a pharmacological alternative. Pilocarpine acts on muscarinic receptors to improve accommodation and depth of focus. Its efficacy and safety, however, require further investigation.

METHODS:

This SRMA followed the Cochrane Handbook and PRISMA guidelines. RCTs comparing pilocarpine to a vehicle in presbyopic patients were included. Efficacy outcomes were the gain of ≥3 lines and ≥2 lines in mesopic, high-contrast binocular distance-corrected near visual acuity (DCNVA) at 3 hours postdose after ≥14 days of treatment. Safety analyses focused on the most consistently reported reactions: headache, blurred vision, eye pain, and pupil size variation.

RESULTS:

Four RCTs with 1531 participants were included. Pooled data showed 33% of pilocarpine users gained ≥3 lines in DCNVA versus 12% in the vehicle group (OR 3.69, 95% CI [2.66-5.14], P < .001) and 63% of pilocarpine users gained ≥2 lines versus 36% (OR 2.94, 95% CI [2.30-3.74], P < .001). Pilocarpine increased the risk of headache (+6.9%; OR 3.02, 95% CI 1.53-5.93), blurred vision (+3.1%; OR 4.93, 95% CI 1.92-12.65), and eye pain (+2.4%; OR 4.26, 95% CI 1.73-10.49), mostly mild and transient. A marked miotic effect was also observed, with a mean pupil size reduction of 1.38 mm versus 0.02 mm in the vehicle group. Sensitivity analysis indicated that removing the VIRGO study reduced heterogeneity, suggesting dosing frequency influence.

CONCLUSION:

Pilocarpine demonstrated short-term efficacy in improving near vision in presbyopic patients, with an increased incidence of specific, mostly mild and transient adverse events and a consistent miotic effect. Further large-scale, long-term RCTs are warranted to confirm benefits, optimize dosing, and fully characterize its safety profile.

01 Nov 2025·NEUROCHEMISTRY INTERNATIONAL

Imbalance of NKCC1/KCC2 contributes to the pathogenesis of primary focal hyperhidrosis

Article

Author: Yu, Feng-Qiang ; Lin, Nan-Long ; Zheng, Ru-Jie ; Li, Xu ; Zhang, Meng-Long ; Lin, Jian-Bo ; Qiu, Rui-Qin

BACKGROUND:

Primary focal hyperhidrosis (PFH) is characterized by excessive sweating in localized regions, significantly impacting patients' quality of life. The imbalance between sodium-potassium-chloride cotransporter 1 (NKCC1) and potassium-chloride cotransporter 2 (KCC2) disrupts chloride ion homeostasis, potentially contributing to the pathogenesis of PFH.

METHODS:

Sweat gland tissues from 76 healthy controls and 76 PFH patients were collected. Expression levels of NKCC1 and KCC2 were assessed using quantitative real-time PCR and Western blotting. Primary sweat gland cells isolated from PFH patients (PFH-SG) and controls (NPFH-SG) were subjected to NKCC1 knockdown via lentiviral shRNA transfection. A hyperhidrosis mouse model was induced by intraperitoneal injection of pilocarpine hydrochloride, and mice were pretreated with the NKCC1 inhibitor bumetanide for one week. Sweat secretion, serum acetylcholine, and chloride ion concentrations were measured. Expression levels of aquaporin 5 (AQP5), brain-derived neurotrophic factor (BDNF), and neuregulin-1 (NRG-1) proteins were analyzed.

RESULTS:

PFH tissues showed significantly elevated NKCC1 and decreased KCC2 expression compared to controls, correlating with lower sweat chloride levels. NKCC1 knockdown in PFH-SG cells reduced elevated AQP5 expression. In vivo, bumetanide treatment markedly reduced sweat secretion, lowered serum acetylcholine, and restored chloride ion concentrations in hyperhidrosis mice. Furthermore, bumetanide treatment significantly decreased expressions of BDNF and NRG-1 in sympathetic ganglia axons, indicating attenuation of sympathetic hyperactivity associated with hyperhidrosis. NKCC1/KCC2 imbalance contributes significantly to PFH pathology.

CONCLUSIONS:

Bumetanide effectively improves this imbalance, reducing excessive sweating and modulating related neurotransmitter signaling, offering potential therapeutic avenues for PFH.

101

News (Medical) associated with Pilocarpine Hydrochloride

05 Aug 2025

·www.globenewswire.com

SynOx Therapeutics Completes Enrollment in Registrational Phase 3 TANGENT Clinical Trial Significantly Ahead of Timeline

Top-Line Results from Study Evaluating Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT) Expected in First Quarter of 2026DUBLIN and OXFORD, United Kingdom and PHILADELPHIA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced completion of patient enrolment in the TANGENT study. TANGENT is the company’s global, multi-centre, randomized, double-blind, placebo-controlled registrational Phase 3 trial of emactuzumab in patients with TGCT who are not amenable to or who would not benefit from surgery. SynOx expects to report top-line data from the study in the first quarter of 2026. Emactuzumab is a potentially best-in-class CSF-1 receptor (CSF-1R) inhibiting monoclonal antibody (mAb). Clinical evaluation to date has demonstrated the compound to be a promising, next-generation mAb therapy with the potential to offer a short treatment cycle, rapid onset and long duration of response that differentiates it from chronically administered oral agents. This potentially best-in-class profile helped drive strong interest in the TANGENT trial among patients and clinical investigators across sites in the United States, Canada, Europe and Asia, leading to rapid study enrollment. “Completion of enrollment in our registrational TANGENT trial marks an important milestone for SynOx and for the TGCT community,” said Elyse Seltzer, M.D., Chief Medical Officer of SynOx Therapeutics. “We are deeply grateful to the patients, families, investigators, and clinical sites whose dedication has made this study possible and allowed SynOx to fully enroll the trial significantly ahead of our projected timeline. We remain committed, data permitting, to delivering a much-needed new treatment option for this debilitating condition.”“This is a transformational time for SynOx as we advance emactuzumab through its pivotal Phase 3 program,” said Ray Barlow, Chief Executive Officer of SynOx. “We’re excited about the next steps and look forward to delivering top-line data that we hope demonstrate how emactuzumab can transform care for patients with this grievous disease.” About the TANGENT StudyTANGENT (ClinicalTrials.gov Identifier: NCT05417789) is a randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy and safety of emactuzumab in patients with TGCT who are not amenable to or would not benefit from surgery. Patients who consent and meet eligibility criteria are randomized in a 2:1 fashion to receive either emactuzumab (1000 mg every two weeks for five doses) or matched placebo. The primary endpoint is objective response rate (ORR) as assessed by RECIST criteria at six months post-randomization. Key secondary endpoints include patient-reported outcomes (PROMIS-PF), functional assessments of range of motion, pain, stiffness, durability of response, and safety. Patients are followed for two years from randomization, with those demonstrating disease progression after the six-month assessment eligible to receive open-label emactuzumab during follow-up. About TGCTTenosynovial Giant Cell Tumour (TGCT), previously termed pigmented villonodular synovitis (PVNS), is a rare, non-malignant but aggressively growing tumour of the synovium, tendon sheaths, and bursa membranes primarily located in knee, hip, and ankle joints and caused by excessive production of CSF-1. It is a chronically debilitating disease that causes loss of function of the affected joints, as well as pain, stiffness, and limited range of motion. While most patients undergo surgery, more than 50% of those with diffuse TGCT experience tumour recurrence within three years. If left untreated, TGCT can cause joint deformity, degenerative changes, and even lead to arthrodesis or amputation in severe cases. About EmactuzumabCSF-1 (or macrophage colony-stimulating factor) is a cytokine that binds to the CSF-1 receptor (CSF-1R), expressed on macrophages and other immune cells. Emactuzumab is a humanised IgG1 monoclonal antibody (mAb) targeting CSF-1R, designed to inhibit and deplete macrophages in tumour tissue. Originally developed by Roche, emactuzumab has shown substantial efficacy in clinical studies in TGCT, including an objective response rate of ~71%, rapid tumour reduction, functional improvement, and good tolerability with a manageable safety profile. Earlier this year, SynOx received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for emactuzumab in the treatment of TGCT, recognizing the serious unmet medical need in this condition. Emactuzumab has also received Orphan Medicinal Product designation from the European Medicines Agency. SynOx is actively exploring further development opportunities for emactuzumab in other macrophage-driven diseases. About SynOx TherapeuticsSynOx Therapeutics Limited is a Dublin, Oxford and Philadelphia-based, late-stage clinical biopharmaceutical company developing emactuzumab, a next-generation, best-in-class monoclonal antibody against CSF-1R, for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other CSF-1-related and macrophage-driven disorders. SynOx is led by an experienced team of industry professionals with a successful track record of developing and bringing products to commercialization. The company is backed by a strong syndicate of premier life science investors including Forbion, Gilde Healthcare, HealthCap, Bioqube Ventures and Medicxi. Contacts: SynOx Therapeutics Ray Barlow Chief Executive Officer Tel: +44 (0) 208 058 5619 Email: enquiries@synoxtherapeutics.com Vida Strategic Partners (on behalf of SynOx) Tim Brons (Media) 415-675-7402 tbrons@vidasp.com

Phase 3Fast TrackOrphan DrugClinical Result

24 Apr 2025

·pharma.economictimes.indiatimes.com

ENTOD Myopia eye drops for children obtains CDSCO approval

Mumbai: Ophthalmic drugs developer ENTOD Pharmaceuticals , eye drops for children with Myopia in the age of 6-12 years has received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) . As per the drug maker, “the drop is a new eye formulation developed to slow the progression of myopia in children aged 6 to 12 years.” The product has been approved following the successful completion of Phase 3 clinical trials in India and will be available in the market as a prescription drug, However, company has not disclosed the name, price and commerical launch timelines of the product. “With myopia rates in India rising from 4 per cent in 1999 to nearly 25 per cent today, and further projections suggesting that by 2050 one in two children could be affected, the need for such a therapy has never been more urgent." Nikkhil K Masurkar, CEO, ENTOD Pharmaceuticals, stated. Last year, the Mumbai-based drug maker came into the spotlight following a controversy over its eye drop PresVu, reported to reduce dependency on reading glasses for individuals affected by presbyopia. However, later the DCGI suspended the approval for the drug and prohibited the company from manufacturing and marketing it. In its official order issued on September 10, 2024 the apex regulator stated that the company tried to justify claims for which approval had not been granted and eye drops have not been approved for any such claim in India that they can reduce the need for reading glasses. Defending the drug the company CEO had said that, “Our approval by the DCGI was based on a valid controlled clinical trial which successfully demonstrated the efficacy and safety of these eye drops in presbyopia patients. As per the Company “Similar eye drops with the same active ingredient and concentration have been approved by the US FDA and marketed in the US for the past three years without any serious complications.” Pilocarpine Hydrochloride Ophthalmic Solution USP 1.25 per cent (PresVu) was approved by the Central Drugs Standard Control Organisation (CDSCO) for the treatment of presbyopia in adults. By Online Bureau ,

Phase 3Drug Approval

14 Apr 2025

·www.globenewswire.com

SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT)

DUBLIN, Ireland and OXFORD, United Kingdom, April 14, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to emactuzumab for the treatment of TGCT patients that are not amenable to or who would not benefit from surgery. Emactuzumab, a potentially best-in-class CSF-1 receptor (CSF-1R) inhibiting monoclonal antibody, is currently being evaluated in the TANGENT study, a global, multi-centre, randomized, double-blind, placebo-controlled registrational Phase 3 trial. TGCT is a rare, non-malignant but aggressively growing tumour of the synovium, tendon sheaths and bursa membranes primarily located in knee, hip, and ankle joints and caused by excessive production of CSF-1. It is a chronically debilitating disease for patients causing loss of function of the affected joints, as well as pain, stiffness and limited range of motion. Receipt of FTD for TGCT was supported by data from Phase 1/2 clinical studies demonstrating rapid, robust tumour reduction and durable response combined with a manageable safety profile. Emactuzumab has also previously received Orphan Medicinal Project designation from the European Medicines Agency. “The granting of FTD for emactuzumab in TGCT highlights the devastating toll that this disease has on patients, as well as the critical need that remains for new treatment options,” said Elyse Seltzer, M.D., Chief Medical Officer of SynOx Therapeutics. “Based on our clinical work to date, we believe that emactuzumab has significant potential to address key patient needs by offering an effective, short-course treatment with rapid onset and a durable response that allows individuals suffering from TGCT to better manage their disease and move forward with their lives. We look forward to completing the ongoing TANGENT study and progressing emactuzumab toward potential commercialization.” About Fast Track DesignationThe FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need. Fast Track status allows for enhanced communication and collaboration between the FDA and drug developers, potentially speeding up the delivery of life-saving treatments to patients. About Tenosynovial Giant Cell Tumour (TGCT)Tenosynovial Giant Cell Tumour (TGCT), previously termed pigmented villonodular synovitis (PVNS), is a type of tumour that affects the soft tissue lining of joints and tendons. TGCTs are categorised as fibrohistiocytic tumours by the WHO classification and are subclassified based on growth patterns (localised and diffuse types) and location (tendon sheath, intra- and extra-articular forms). TGCTs are locally destructive and can be aggressive. The disease causes significant joint pain, stiffness, loss of function and reduced quality of life. While most patients undergo surgery, more than 50% of those with diffuse TGCT experience tumour recurrence within three years. If left untreated, TGCT can cause joint deformity, degenerative changes, and even lead to arthrodesis or amputation in severe cases. About CSF-1 and EmactuzumabCSF-1 (or macrophage colony-stimulating factor) is a cytokine that binds to the CSF-1 receptor (CSF-1R), expressed on macrophages and other immune cells. Emactuzumab is a humanised IgG1 monoclonal antibody targeting CSF-1R, designed to inhibit and deplete macrophages in tumour tissue. Originally developed by Roche, emactuzumab has shown substantial efficacy in clinical studies in TGCT, including an objective response rate of ~71%, rapid tumour reduction, functional improvement, and good tolerability with a manageable safety profile. Emactuzumab may also have utility in other macrophage-driven diseases, and SynOx is actively exploring further development opportunities in these areas. Additional details regarding the ongoing registrational Phase 3 TANGENT study can be found on ClinicalTrials.gov (Identifier: NCT05417789). About SynOx TherapeuticsSynOx Therapeutics Limited is a Dublin and Oxford-based, late-stage clinical biopharmaceutical company developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other CSF-1-related and macrophage-driven disorders. SynOx is led by an experienced team of industry professionals with a successful track record of developing and bringing products to commercialization. The company is backed by a strong syndicate of premier life science investors including Forbion, Gilde Healthcare, HealthCap, Bioqube Ventures and Medicxi. Contacts: SynOx Therapeutics Ray Barlow Chief Executive Officer Tel: +44 (0) 208 058 5619 Email: enquiries@synoxtherapeutics.com Vida Strategic Partners (on behalf of SynOx) Tim Brons (Media) 415-675-7402 tbrons@vidasp.com

Fast TrackPhase 3Orphan Drug

100 Deals associated with Pilocarpine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D02200	Pilocarpine Hydrochloride	S01EB01 N07AX01	DB01085

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Presbyopia	United States	AbbVie, Inc.	28 Oct 2021
Acute angle-closure glaucoma	United States	Sandoz, Inc.	22 Jun 2010
Ocular Hypertension	United States	Alcon Laboratories, Inc.	01 Oct 1984
Xerostomia	Canada	Alcon Canada, Inc.	31 Dec 1951

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Kerato conjunctivitis sicca	Phase 2	United States	Glaukos Corp.	03 Jan 2022
Xerophthalmia	Phase 2	United States	Glaukos Corp.	-
Miosis	Phase 1	United States	Novus Vision LLC	30 Jan 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05393895 (CTgov)	Phase 3	Presbyopia	178	CSF-1 (CSF-1)	czckqyierl = wmceiwmimz lircbywgkf (wymvazqavj, ivuvhvalgy - jnguxjoabp) View more	-	11 Jun 2025
				Vehicle (Vehicle)	czckqyierl = cldedghqbs lircbywgkf (wymvazqavj, hfkpngudld - schlukjadt) View more
NCT04599933 (NEAR-1, CTgov)	Phase 3	Presbyopia	309	CSF-1 (CSF-1)	hmkufayhcz = iossrpiwgw yliejlzuxt (ceoejkpnqf, igkgcvockr - twphodyyjl) View more	-	28 Nov 2023
				Vehicle (Vehicle)	hmkufayhcz = tquvogheul yliejlzuxt (ceoejkpnqf, xlqddhyfoa - sapiowhvoh) View more
NCT04599972 (NEAR-2, CTgov)	Phase 3	Presbyopia	304	CSF-1 (CSF-1)	xuamihgfxj = wfsasyxrxp wpikcmdiqh (cehrkpgzxm, yvknawavgo - wsvaanrruu) View more	-	28 Nov 2023
				Vehicle (Vehicle)	xuamihgfxj = vpwegvpbkz wpikcmdiqh (cehrkpgzxm, baghcbsiue - vdsurecifo) View more
NCT04675151 (CTgov)	Phase 2	Presbyopia	150	LDP+POS (POS 0.75% First, Then LDP 0.4%)	hpjqonpmsc = zbiqngyxje tvlnkzzovk (zecsgisfwl, dnzvdbqogk - ecomgnnzot) View more	-	02 Aug 2023
				LDP+POS (POS 0.75% First, Then LDP Vehicle)	hpjqonpmsc = hhkzadccyc tvlnkzzovk (zecsgisfwl, sjupdbvkoi - ctsxhdjnii) View more
GEMINI (ARVO2023)	Phase 3	Presbyopia	750	Pilocarpine HCl ophthalmic solution 1.25%	thdbzznwmr(cahvtcewtg) = ypcgxebive ejcdchnpce (caceeidwdg ) View more	-	01 Jun 2023
				Vehicle	thdbzznwmr(cahvtcewtg) = yyovzimzha ejcdchnpce (caceeidwdg ) View more
VEGA-1 (ARVO2023)	Phase 2	Presbyopia	150	0.75% Phentolamine Ophthalmic Solution (POS)	ngupxndund(wdhookcefa) = mljinzkykb lrzkuynbyi (fljhfgfyco )	Positive	23 Apr 2023
				0.4% Low Dose Pilocarpine (LDP)	ngupxndund(wdhookcefa) = nquefjelml lrzkuynbyi (fljhfgfyco )
NCT03804268 (GEMINI 1, ARVO2023)	Phase 3	Presbyopia	323	Pilocarpine hydrochloride ophthalmic solution 1.25%	vnkxkyadcv(pqrnocliob) = vjhwkrfarg byzpccbrop (zinvzlrshn )	-	23 Apr 2023
				Vehicle	vnkxkyadcv(pqrnocliob) = ibnzqofdnn byzpccbrop (zinvzlrshn )
NCT04983589 (Virgo, CTgov)	Phase 3	Presbyopia	230	Vehicle (Vehicle)	uvhxoghisr = diqqmbexpj vtwauzzsbb (kobvvvqoor, fajeimisxd - vgzehvgjbk) View more	-	21 Mar 2023
				Pilocarpine HCl (AGN-190584)	uvhxoghisr = ljtkjgbwsb vtwauzzsbb (kobvvvqoor, lrtxvtvbzq - dfmchfqbkw) View more
NCT05238233 (CTgov)	Phase 4	Anisocoria	11	Reichert phoropter+Proparacaine Hydrochloride+Tropicamide+1% Pilocarpine	pwqtdqlpxt = lwoywdqdxn naiwkjzhfj (xaycssygub, vfasbzlqmq - adbzumbzwi) View more	-	07 Mar 2023
NCT03885011 (CTgov)	Phase 2	Presbyopia	166	pilocarpine HCl+diclofenac Na (CSF-1-FDC)	mvqfsbiibo = mhzkftihjc xxsnozjbeg (ypmklscxtn, zzvofjiotz - ekglwcczeu) View more	-	26 Jan 2023
				pilocarpine HCl (Pilo)	mvqfsbiibo = jxnyhuqgix xxsnozjbeg (ypmklscxtn, fjkcsribah - cpnqvjavqm) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Pilocarpine Hydrochloride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation